Lyubov Zholudeva

Independent Researcher

Publications

400

Citations

H-Index

i10-Index

2yr Mean Cite

True

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. OA

R. Ferris, R. Haddad, C. Even, M. Tahara, M. Dvorkin - Annals of Oncology, 2020

Cited by 310 Semantic Scholar

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

L. Licitra, R. Haddad, C. Even, M. Tahara, M. Dvorkin - Journal of Clinical Oncology, 2019

Cited by 36 Semantic Scholar

Research Topics

Cancer Immunotherapy and Biomarkers (2) Head and Neck Cancer Studies (1) Lung Cancer Treatments and Mutations (1) Radiopharmaceutical Chemistry and Applications (1) Peptidase Inhibition and Analysis (1)

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers

Lyubov Zholudeva

Publication & Citation Trends

Publications

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. OA

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Research Topics

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back